These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19740630)

  • 1. Signs of striatal dopamine transporter density increase in association with improvement of tardive dyskinesia in a patient with schizophrenia, as demonstrated by a DAT scan.
    Rizos EN; Chatziioannou S; Douzenis A; Siafakas N; Katsantoni E; Nikolaidou P; Papathanasiou M; Lykouras L
    Eur Neuropsychopharmacol; 2010 Feb; 20(2):132-6. PubMed ID: 19740630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased striatal dopamine transporter levels, as indicated by a DAT scan, induced by ziprasidone in association to improvement of tardive dyskinesia--a case report.
    Rizos EN; Chatziioannou S; Siafakas N; Douzenis A; Katsantoni E; Mandrapilia A; Bacalis S; Fotiadis C; Lykouras L
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):1135-6. PubMed ID: 20460141
    [No Abstract]   [Full Text] [Related]  

  • 3. Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine.
    Vesely C; Küfferle B; Brücke T; Kasper S
    Int Clin Psychopharmacol; 2000 Jan; 15(1):57-60. PubMed ID: 10836289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia.
    Yoder KK; Hutchins GD; Morris ED; Brashear A; Wang C; Shekhar A
    Schizophr Res; 2004 Dec; 71(2-3):371-5. PubMed ID: 15474908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quetiapine-induced improvement of tardive dyskinesia in three patients with schizophrenia.
    Alptekin K; Kivircik BB
    Int Clin Psychopharmacol; 2002 Sep; 17(5):263-4. PubMed ID: 12177588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.
    Bressan RA; Jones HM; Pilowsky LS
    J Psychopharmacol; 2004 Mar; 18(1):124-7. PubMed ID: 15107196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tardive dyskinesia in a patient treated with quetiapine.
    Rizos E; Douzenis A; Gournellis R; Christodoulou C; Lykouras LP
    World J Biol Psychiatry; 2009; 10(1):54-7. PubMed ID: 19673087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tardive dyskinesia related to quetiapine and confirmed by a DAT scan.
    Chatziioannou SN; Rizos EN; Kallergi M; Douzenis A; Apostolopoulos A; Bacalis S; Lykouras L
    J Clin Psychopharmacol; 2011 Aug; 31(4):535-8. PubMed ID: 21720231
    [No Abstract]   [Full Text] [Related]  

  • 9. Tardive dyskinesia with quetiapine.
    Ghelber D; Belmaker RH
    Am J Psychiatry; 1999 May; 156(5):796-7. PubMed ID: 10327920
    [No Abstract]   [Full Text] [Related]  

  • 10. A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients.
    Mané A; Gallego J; Lomeña F; Mateos JJ; Fernandez-Egea E; Horga G; Cot A; Pavia J; Bernardo M; Parellada E
    Psychiatry Res; 2011 Oct; 194(1):79-84. PubMed ID: 21831607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone.
    Nelson MW; Reynolds RR; Kelly DL; Conley RR
    Clin Neuropharmacol; 2003; 26(6):297-8. PubMed ID: 14646608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine transporter density in patients with tardive dyskinesia: a single photon emission computed tomography study.
    Lavalaye J; Sarlet A; Booij J; Linszen DH; Reneman L; Gersons BP; van Royen EA
    Psychopharmacology (Berl); 2001 Apr; 155(1):107-9. PubMed ID: 11374328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of dopamine receptor occupancy by [123I]IBZM-SPECT in schizophrenic patients treated with quetiapine.
    Pávics L; Szekeres G; Ambrus E; Kéri S; Kovács Z; Argyelán M; Kanyó B; Csernay L; Janka Z
    Nucl Med Rev Cent East Eur; 2004; 7(2):129-33. PubMed ID: 15968599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies.
    Costa A; Riedel M; Müller U; Möller HJ; Ettinger U
    Synapse; 2011 Oct; 65(10):998-1005. PubMed ID: 21404331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine transporter availability in drug-naïve patients with schizophrenia and later psychotic symptoms severity.
    Tseng HH; Chen KC; Chen PS; Lee IH; Chang WH; Yao WJ; Chiu NT; Yang YK
    Schizophr Res; 2017 Dec; 190():185-186. PubMed ID: 28364963
    [No Abstract]   [Full Text] [Related]  

  • 16. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
    Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
    Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine.
    Tauscher J; Küfferle B; Asenbaum S; Brücke T; Kasper S
    Psychopharmacology (Berl); 1997 Sep; 133(1):102-5. PubMed ID: 9335088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients.
    Schmitt GJ; Frodl T; Dresel S; la Fougère C; Bottlender R; Koutsouleris N; Hahn K; Möller HJ; Meisenzahl EM
    Eur Arch Psychiatry Clin Neurosci; 2006 Mar; 256(2):115-21. PubMed ID: 16284713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.
    Peritogiannis V; Tsouli S
    J Psychopharmacol; 2010 Jul; 24(7):1121-5. PubMed ID: 19395427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive impairment in schizophrenia is associated with prefrontal-striatal functional hypoconnectivity and striatal dopaminergic abnormalities.
    Yang KC; Yang BH; Liu MN; Liou YJ; Chou YH
    J Psychopharmacol; 2024 Jun; 38(6):515-525. PubMed ID: 38853592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.